Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Ulm, Germany. In Support Care Cancer, Feb 2016
UNASSIGNED: The recombinant human granulocyte colony-stimulating factor (G-CSF) known as filgrastim (Tevagrastim(®), Ratiograstim(®), Biograstim(®)) in Europe (approved in 2008) and tbo-filgrastim (Granix(®)) in the USA (approved in 2012; Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel) is indicated to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Neutrophil ageing is regulated by the microbiome.
New York City, United States. In Nature, Oct 2015
Aged neutrophils upregulate CXCR4, a receptor allowing their clearance in the bone marrow, with feedback inhibition of neutrophil production via the IL-17/G-CSF axis, and rhythmic modulation of the haematopoietic stem-cell niche.
Anticytokine autoantibody-associated immunodeficiency.
Bethesda, United States. In Annu Rev Immunol, 2013
Other anticytokine autoantibodies may contribute to an infectious phenotype such as anti-granulocyte colony stimulating factor and anti-IFN-α autoantibodies, although the strength of the association is less clear.